MedTrace Logo

Estrogen Diastolic Heart Failure

NCT02693002 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-08-08

Study results available
· View outcomes & findings →

Summary

Peri-menopausal women will be randomized to hormone replacement therapy or placebo for 12 weeks to determine if markers of systolic and diastolic function change by echocardiography as well as laboratory markers of heart failure, including b-type natriuretic peptide (BNP).

Conditions

Interventions

DRUG

Estradiol/Norethindrone acetate

Estradiol/Norethindrone acetate 1mg/0.5 mg

DRUG

Placebo

inactive ingredient

Sponsors & Collaborators

  • Gretchen Wells

    lead OTHER

Principal Investigators

  • Gretchen L Wells, MD, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02693002 on ClinicalTrials.gov